Q-omics provides the consensus-scored MRPL19 profile across patient tissues and cancer cell-line models. MRPL19 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MRPL19 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, MRPL19 protein abundance shows 21,876 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, BLCA, and LSCC as cancer lineages where MRPL19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL19 survival associations across molecular data types. MRPL19 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL19 RNA expression–survival associations across cancer types. High MRPL19 expression shows unfavorable associations in MESO, ACC, KICH, HNSC and CESC, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MRPL19 RNA expression.
This table summarizes MRPL19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPL19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL19 shows lower tumor expression in KIRC and higher tumor expression in BLCA, HNSC, LUAD, STAD and LUSC. The BLCA box plot shows higher MRPL19 RNA expression in tumor versus normal tissue (log2 FC = +1.099, t-test p < 0.001).
This table shows molecular features associated with MRPL19 in patient tissues and cancer cell lines. In patient samples, MRPL19 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPL19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SOFT_TISSUE.
